Previstage GCC colorectal cancer staging test provides prognostic information based on the tumour burden measured at the molecular level in the lymph nodes, a key prognostic factor to determine the risk of recurrence of cancer patients.
The study showed that higher detection levels of GCC in lymph nodes were associated with increased risk of all-cause mortality, disease-specific survival, and disease-free survival.
In the trial, the 5-year recurrence risks were estimated at 11% and 32% for the low and high risk groups respectively.
DiagnoCure specializes in developing and commercializing high-value cancer diagnostic tests.